Boston Scientific highlights strong performance in second quarter of 2014

Boston Scientific has announced its financial results for the second quarter of 2014, during which it generated sales of $1.87 billion (1.1 billion pounds).

This represented a four percent year-on-year increase on both an operational and reported basis, falling towards the upper end of its previously stated guidance range. Meanwhile, adjusted earnings per share came to $0.21, compared to $0.18 a year ago.

Its rhythm management, MedSurg and cardiovascular business units all saw improvements, while its European and emerging market performances were both particularly strong. The launch and approval of several new products aided this momentum.

Additionally, a definitive agreement to acquire the interventional division of Bayer was agreed, which is expected to drive growth in the peripheral atherectomy and thrombectomy categories, as well as a deal to purchase IoGyn, creator of the hysteroscopic intrauterine tissue removal system Symphion.

Mike Mahoney, president and chief executive officer of Boston Scientific, said: "We are pleased with the improvement in both our interventional cardiology and cardiac rhythm management divisions. We remain confident in both our strategy and in our outlook for the year."